Methods of treating castration-resistant and castration-sensitive prostate cancer using a compound having the following structure (I):

##STR00001##

or a pharmaceutically acceptable salt or zwitterionic form thereof, are provided.

Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by dysregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).

Methods and compositions for inducing cell death in cells with FET-fused oncogenes, as well as methods for treating tumors with FET-fused oncogenes, such as cells and tumors associated with Ewing's sarcoma and fibromyxoid Iposarcoma. Oncogenes may include the EWS-FLI1 oncogene, FUS-FLI1 oncogene, FUS-CHOP oncogene, etc. The methods feature herein administering to a patient with a FET-fused oncogene tumor a combination of a DNA damaging agent and a transcription inhibitor. The combination of the transcription inhibitor and DNA damaging agent causes death of cells in the tumor.

Methods and compositions for inducing cell death in cells with FET-fused oncogenes, as well as methods for treating tumors with FET-fused oncogenes, such as cells and tumors associated with Ewing's sarcoma and fibromyxoid Iposarcoma. Oncogenes may include the EWS-FLI1 oncogene, FUS-FLI1 oncogene, FUS-CHOP oncogene, etc. The methods feature herein administering to a patient with a FET-fused oncogene tumor a combination of a DNA damaging agent and a transcription inhibitor. The combination of the transcription inhibitor and DNA damaging agent causes death of cells in the tumor.

Methods and compositions for inducing cell death in cells with FET-fused oncogenes, as well as methods for treating tumors with FET-fused oncogenes, such as cells and tumors associated with Ewing's sarcoma and fibromyxoid Iposarcoma. Oncogenes may include the EWS-FLI1 oncogene, FUS-FLI1 oncogene, FUS-CHOP oncogene, etc. The methods feature herein administering to a patient with a FET-fused oncogene tumor a combination of a DNA damaging agent and a transcription inhibitor. The combination of the transcription inhibitor and DNA damaging agent causes death of cells in the tumor.

A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.

A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.

This document relates to methods and materials involved in assessing and/or treating mammals (e g , humans) having cancer. For example, methods and materials that can be used to determine whether or not the cancer is likely to be responsive to a particular cancer treatment (e.g., a cancer immunotherapy or a cancer chemotherapy) are provided. For example, methods and materials that can be used to treat a mammal by administering one or more cancer treatments that is/are selected based, at least in part, on whether or not the mammal is likely to be responsive to a particular cancer treatment also are provided.

This document relates to methods and materials involved in assessing and/or treating mammals (e g , humans) having cancer. For example, methods and materials that can be used to determine whether or not the cancer is likely to be responsive to a particular cancer treatment (e.g., a cancer immunotherapy or a cancer chemotherapy) are provided. For example, methods and materials that can be used to treat a mammal by administering one or more cancer treatments that is/are selected based, at least in part, on whether or not the mammal is likely to be responsive to a particular cancer treatment also are provided.

Described herein are methods of treating a cancer, for example, a hematologic malignancy or a solid tumor, in a patient in need thereof, comprising administering to the patient a Bcl-2 inhibitor in combination with a second anti-cancer agent.